Payment overview · 2025
General Payments
$121.16
6 reported records · 2 companies
Healthcare provider profile · identity verified
Alexander C Chan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · NEW YORK, NY · NPI 1568427243
Verified facts
What the public records show
CMS Open Payments records show Alexander C Chan, M.D. received $121.16 in general payments during 2025 across 6 reported records.
GlaxoSmithKline, LLC. accounted for 74.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $90.08 | 74.3% | 4 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $31.08 | 25.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $121.16 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $90.08 | 4 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $31.08 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
58 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1383 | 303 |
| Losartan Potassium | Losartan Potassium | 926 | 199 |
| Amlodipine Besylate | Amlodipine Besylate | 909 | 195 |
| Vascepa | Icosapent Ethyl | 577 | 98 |
| Metformin Hcl | Metformin Hcl | 485 | 104 |
| Simvastatin | Simvastatin | 462 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 454 | 94 |
| Famotidine | Famotidine | 450 | 108 |
| Raloxifene Hcl | Raloxifene Hcl | 444 | 103 |
| Omeprazole | Omeprazole | 418 | 125 |
| Tamsulosin Hcl | Tamsulosin Hcl | 416 | 101 |
| Ammonium Lactate | Ammonium Lactate | 401 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 379 | 101 |
| Alendronate Sodium | Alendronate Sodium | 376 | 86 |
| Farxiga | Dapagliflozin Propanediol | 372 | 80 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 351 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 348 | 80 |
| Celecoxib | Celecoxib | 301 | 95 |
| Mometasone Furoate | Mometasone Furoate | 286 | 120 |
| Fluticasone Propionate | Fluticasone Propionate | 285 | 66 |
| Januvia | Sitagliptin Phosphate | 273 | 46 |
| Azithromycin | Azithromycin | 272 | 202 |
| Pioglitazone Hcl | Pioglitazone Hcl | 265 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 257 | 48 |
| Metformin Hcl Er | Metformin Hcl | 254 | 44 |
| Allopurinol | Allopurinol | 253 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 243 | 127 |
| Gabapentin | Gabapentin | 240 | 63 |
| Finasteride | Finasteride | 214 | 43 |
| Glimepiride | Glimepiride | 181 | 30 |
| Glipizide Er | Glipizide | 181 | 37 |
| Meclizine Hcl | Meclizine Hcl | 179 | 96 |
| Tradjenta | Linagliptin | 175 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 165 | 67 |
| Jardiance | Empagliflozin | 163 | 27 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 156 | 33 |
| Azelastine Hcl | Azelastine Hcl | 153 | 52 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 152 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 49 |
| Donepezil Hcl | Donepezil Hcl | 143 | 28 |
| Diclofenac Epolamine | Diclofenac Epolamine | 124 | 26 |
| Ezetimibe | Ezetimibe | 122 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 120 | 92 |
| Baclofen | Baclofen | 118 | 47 |
| Atenolol | Atenolol | 115 | 25 |
| Montelukast Sodium | Montelukast Sodium | 109 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 107 | 23 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 107 | 23 |
| Lisinopril | Lisinopril | 106 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 102 | 49 |
| Bepotastine Besilate | Bepotastine Besilate | 99 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 18 |
| Hydrocortisone | Hydrocortisone | 93 | 28 |
| Dexlansoprazole Dr | Dexlansoprazole | 92 | 19 |
| Meloxicam | Meloxicam | 90 | 42 |
| Furosemide | Furosemide | 89 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 88 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 16 |
| Carvedilol | Carvedilol | 87 | 16 |
| Nebivolol Hcl | Nebivolol Hcl | 86 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 24 |
| Ketoconazole | Ketoconazole | 82 | 29 |
| Mupirocin | Mupirocin | 77 | 39 |
| Ciclopirox | Ciclopirox | 76 | 19 |
| Irbesartan | Irbesartan | 76 | 16 |
| Amoxicillin | Amoxicillin | 75 | 53 |
| Xarelto | Rivaroxaban | 75 | 16 |
| Promethazine Hcl | Promethazine Hcl | 73 | 56 |
| Acarbose | Acarbose | 70 | 11 |
| Lidocaine | Lidocaine | 70 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 66 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 65 | suppressed |
| Glipizide | Glipizide | 64 | 11 |
| Rybelsus | Semaglutide | 63 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 62 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | suppressed |
| Folic Acid | Folic Acid | 59 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 58 | 28 |
| Methimazole | Methimazole | 58 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 58 | 44 |
| Colchicine | Colchicine | 55 | 33 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 55 | 15 |
| Clotrimazole | Clotrimazole | 53 | 25 |
| Loperamide | Loperamide Hcl | 51 | 42 |
| Dapagliflozin | Dapagliflozin Propanediol | 50 | 14 |
| Valacyclovir | Valacyclovir Hcl | 50 | 27 |
| Alcohol Pads | Alcohol Antiseptic Pads | 49 | 31 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 47 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | suppressed |
| Dutasteride | Dutasteride | 44 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 44 | 17 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Valsartan | Valsartan | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 42 | suppressed |
| Creon | Lipase/Protease/Amylase | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 40 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 37 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Eliquis | Apixaban | 37 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Procto-Med Hc | Hydrocortisone | 34 | 13 |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Niacin Er | Niacin | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Memantine Hcl Er | Memantine Hcl | 30 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | 25 |
| Ramelteon | Ramelteon | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 27 | 27 |
| Naproxen | Naproxen | 27 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 26 | suppressed |
| Fluocinonide | Fluocinonide | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23 | 23 |
| Digoxin | Digoxin | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 22 | suppressed |
| Prednisone | Prednisone | 22 | 16 |
| Repaglinide | Repaglinide | 22 | suppressed |
| Silodosin | Silodosin | 22 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 21 | 21 |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 11 |
| Ciclopirox | Ciclopirox Olamine | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 17 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Edarbi | Azilsartan Medoxomil | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | 12 |
| Olanzapine | Olanzapine | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Denta 5000 Plus | Fluoride (Sodium) | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ozempic | Semaglutide | 14 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 14 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Sf 5000 Plus | Fluoride (Sodium) | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $121.16 · 6 records | GlaxoSmithKline, LLC. | Fluad, Flucelvax, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error